Why Clenpiq?
Why CLENPIQ?
CLENPIQ–Prep your patients for a successful colonoscopy
CLENPIQ is the next-generation low-volume,
ready-to-drink bowel prep1
1
LOWEST VOLUME OF ACTIVE MEDICATION COMPARED WITH SUPREP®, PLENVU®, SUFLAVETM, AND MoviPrep®1-5*
2
NO MIXING OR DILUTING1
3
SUPPLIED IN TWO 5.8-OZ, READY-TO-DRINK BOTTLES1*
*Additional clear liquids are required for hydration.1-5
Split-dose CLENPIQ demonstrates proven efficacy1,6†
88% of patients achieved successful cleansing of the entire colon1,6†
Primary Endpoint: Proportion of patients with successful colon cleansing, defined as “excellent” or “good.”6†
Scoring was performed before washing and suctioning using the Aronchick Scale.6
†Trial Design: The efficacy and safety of CLENPIQ were evaluated in a randomized, multicenter, controlled, assessor-blinded trial. CLENPIQ® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution (SPMC) was administered in a split-dose regimen against an oral powder (for reconstitution) (P/MC powder) and efficacy was evaluated using 2 different measurement scales.6 In this trial, CLENPIQ patients were instructed to drink at least five 8-ounce glasses of clear liquid within 5 hours of the first dose of CLENPIQ and at least four 8-ounce glasses of clear liquid within 4 hours of the second dose.6
Split-dose CLENPIQ demonstrated proven efficacy in cleansing
all segments of the colon6†
Secondary efficacy endpoints were the proportion of patients with successful cleansing of the ascending, transverse, and descending colon, defined as a segmental score of “3” or “2.”6
Scoring was performed after washing and suctioning.6
†Trial Design: The efficacy and safety of CLENPIQ were evaluated in a randomized, multicenter, controlled, assessor-blinded trial. CLENPIQ® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution (SPMC) was administered in a split-dose regimen against an oral powder (for reconstitution) (P/MC powder) and efficacy was evaluated using 2 different measurement scales.6
Would you like to receive a CLENPIQ sample?
Please click the button to fill out your information.
Watch a colonoscopy of a patient who has used CLENPIQ
CLENPIQ–Established safety profile1
- The most common adverse reactions (≥2%) observed in the adult CLENPIQ split-dose clinical trial were nausea (3%), headache (3%), hypermagnesemia (2%), abdominal pain (2%), and dehydration or dizziness (2%).1
- Hypermagnesemia levels were transient and not associated with any clinically significant sequelae. Eight of the 9 patients with hypermagnesemia returned to baseline within 24 to 48 hours. One patient returned to baseline by the day 7 follow-up visit.1,6
- 1% of patients taking CLENPIQ experienced vomiting.6
Helpful CLENPIQ resources
A successful bowel prep is our goal with CLENPIQ. See these available resources to help you and your patients learn more about split-dose CLENPIQ and how to properly complete prep.
Instructions for Use
Clarity is priority for colonoscopies. Here are straightforward instructions to help you walk your patients through a bowel prep with CLENPIQ.
DOWNLOAD
Watch and Learn
This video is a helpful tool to share with your patients to help explain step-by-step instructions for taking CLENPIQ.
Watch NowRequest a Rep
Schedule an office visit with a CLENPIQ representative or sign up to receive helpful materials and updates.
"*" indicates required fields
References: 1. CLENPIQ®. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2023. 2. SUPREP® Bowel Prep Kit. Prescribing Information. Braintree, MA: Braintree Laboratories, Inc; 2020. 3. PLENVU®. Prescribing Information. Bridgewater, NJ: Salix Pharmaceuticals; 2023. 4. SUFLAVE™. Prescribing Information. Braintree, MA: Braintree Laboratories, Inc; 2023. 5. MoviPrep®. Prescribing Information. Bridgewater, NJ: Salix Pharmaceuticals; 2023. 6. Hookey L, Bertiger G, Johnson II KL, Ayala J, Seifu Y, Brogadir SP. Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial. Therap Adv Gastroenterol. 2019;12:1756284819851510.
Next: